Indications and medication precautions for Repotrectinib in Laos
Repotrectinib is a targeted therapy drug mainly used for ROS1 positive non-small cell lung cancer and NTRK gene fusion solid tumors. When using it, attention should be paid to adverse reactions such as central nervous system effects and liver toxicity. The following provides a detailed explanation from two aspects: indications and medication precautions, covering treatment targets and special monitoring requirements.
1. Indications
(1) Non small cell lung cancer (NSCLC): Used to treat adult patients with locally advanced or metastatic non-small cell lung cancer who are ROS1 positive, designated as an orphan drug by the US FDA.
(2) NTRK gene fusion solid tumor: Used for locally advanced or metastatic NTRK positive solid tumors in adult and pediatric patients aged 12 years and above, with no known drug-resistant mutations.
2. Medication precautions
(1) Central nervous system impact
May cause dizziness, ataxia, or cognitive impairment, driving or operating machinery should be avoided during medication.
(2) Interstitial lung disease/pneumonia
New or worsening respiratory symptoms need to be monitored, and suspected cases should stop taking medication immediately.
(3) Hepatotoxicity
Monitor liver function every 2 weeks during the first month of treatment, and conduct regular follow-up examinations. If any abnormalities occur, adjust the dosage or discontinue medication.
(4) Bone fracture
When pain or abnormal activity occurs, it is necessary to evaluate it in a timely manner and adjust the treatment plan if necessary.
(5) Embryo fetal toxicity
Women of childbearing age should use non hormonal contraceptive measures and avoid pregnancy during treatment and within 2 months after discontinuation of medication.
(6) Handling of missed services
Skip missed doses and take the next dose at the regular time. Do not take double doses.
(7) Special populations
Breastfeeding should be stopped during the treatment period and within 10 days after discontinuation of medication for lactating women; Elderly patients do not need to adjust their dosage.
Disclaimer：《Indications and medication precautions for Repotrectinib in Laos》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！